ПОРУШЕННЯ БАЛАНСУ ПРО-ТА ПРОТИЗАПАЛЬНИХ ЦИТОКІНІВ У ПАЦІЄНТІВ З ЛЕГЕНЕВОЮ ГІПЕРТЕНЗІЄЮ НА ТЛІ ХРОНІЧНОГО ОБСТРУКТИВНОГО ЗАХВОРЮВАННЯ ЛЕГЕНЬ З СУПУТНЬОЮ ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ

Гетман О. А.; Крахмалова О. О.

doi:10.31435/rsglobal_ws/30082018/6063

Гетман О. А. ДУ «Національний інститут терапії ім. Л. Т. Малої НАМН України», Харків
Крахмалова О. О. ДУ «Національний інститут терапії ім. Л. Т. Малої НАМН України», Харків

DOI: https://doi.org/10.31435/rsglobal_ws/30082018/6063

Keywords: osteopontin, COPD, coronary artery disease, pulmonary hypertension

Abstract

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lung associated with progressive airflow limitation. There is growing recognition that the inflammatory state associated with COPD is not confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs. However, there is insufficient data on the potential role of systemic inflammation in the formation of pulmonary hypertension, secondary to COPD. Thus, our goal was to investigate the degree of systemic inflammation that is reflected in the level of interleukin-4 and interleukin (IL-2) exchange in patients with COPD and coronary artery disease (IHD) with and without pulmonary hypertension. METHODS: 121 patients with COPD and stable coronary heart disease (mean age [M +/- SD], 60.7 ± 9.7 years, mean FEV1, 46.2 ± 18.1%) were screened into the study, mean pulmonary artery preasure was measured using echocardiography. Osteopontin and IL-2 levels in the serum were evaluated using ELISA kits. Patients were divided into 2 groups: 1 group with signs of pulmonary hypertension (68 patients); and 53 patients without Pulmonary hypertension (2-group). RESULTS: IL-2 concentrations were in 1 group - 9.8 [7.3; 13.1] and 2.2 [0.9; 3.0] in 2 group respectively. For IL-4, the levels were 2.5 [1.8; 2.9] – 1 group, and in the control group (without PH) 3.5 [0.59; 10.0] does not exceed the values of healthy donors. Correlation analysis shows that in the first group there was a positive correlation between the duration of COPD and the level of IL-2 (r = 0.33, p = 0.04) and the negative correlation between osteopontin, IL -2 with a FEV1 (r = -0.84); FLC (r = -0.55). There is a high correlation between osteopontin (r = -0.45), IL-2 (r = -0.60), and a 6-minute walk test and IL-2 and the Borg dyspnea scale (r = 0, 42) after a 6-minute walk test. Pulmonary hypertension is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD and CAD.

References

Багрий А. Е. Дядик А. И. Моногарова Н. Е. Вишневецкий И. И. Легочная гипертензия и хроническое легочное серце (cor pulmonale). – Газета «Новости медицини и фармации». – кардиология (241). – 2008. - (Тематический номер).

Коноплева Л. Ф.Дифференцированное лечение легочной гипертензии и ее осложнений. Здоров’я України. –червень,2011.- с.45-47

Крахмалова Е. О., Гетман Е. А Синдром легочной гипертензии при коморбидности хронической обструктивное болезни легких и ишемической болезни сердца / Е. А. Крахмалова, Е. А. Гетман //Украинский терапевтический журнал. - 2017. - No 1. - С. 81-88.

Митюшова, Е. В. Роль интерлейкина-2 и JAK/STAT сигнализации в экспрессии рецептора интерлейкина-2 в лимфоцитах человека [Текст]: дис. ... канд. биол. наук: 03.03.04 / Елена Викторовна Митюшова. – СПб., 2013. – 101 c.

Середюк В. Н. Оцінка діастолічної і систолічної функції міокарда правого шлуночка у хворих на хронічне легеневе серце в стадії декомпенсації // Архів клін. мед. – 2005. – No 1. – С. 58-62.

Фещенко Ю.І. Хронічні обструктивні захворювання легень: проблемні питання // Нова медицина. — 2005. – No 1 (18). – С. 18-20.

Badesch D. B., Champion H. C., Sanchez M. A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54 (1 supl.): S55–66.

Boutin-Forzano S., Moreau D., Kalaboka S. et al. Reported prevalence and co-morbidity of asthma, chronic bronchitis and emphysema: a pan-European estimation. Int. J. Tuberc. Lung Dis. 2007; 11: 695–702.

Brown D.M. [et al.] Deformability and CD11/CD18 expression of sequestered neutrophils in normal and inflamed lungs [Text] // Am. J. Respir. Cell Mol. Biol. – 1995. – Vol. 13, No 5. – P. 531-539.

Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur. Respir. J. 2008; 32: 1371– 1385.

Chaouat A., Savale L., Chouaid C. et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136: 678–687.

Davoine, F. Eosinophil Cytokines, Chemokines, and Growth Factors: Emerging Roles in Immunity [Text] / F. Davoine, P. Lacy // Front Immunol. – 2014. – Vol. 5. – P. 570.

Eddahibi S., Chaouat A., Morrell N. et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839–1844.

Eddahibi S., Chaouat A., Tu L. et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 475–476.

Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67–119.

Hoeper M.M., Welte T. Systemic inflammation, COPD, and pulmonary hypertension. Chest 2007; 131: 634–635.

Joppa, Pavol & Petrasova, Darina & Stancák, Branislav & Tkacova, Ruzena. (2006). Systemic Inflammation in Patients With COPD and Pulmonary Hypertension. Chest. 130. 326-33.10.1378/chest.130.2.326.

Lee, J.S. Serum levels of IL-8 and icam-1 as biomarkers for progressive massive fibrosis in coal workers' pneumoconiosis [Text] / J.S. Lee, J.H. Shin, B.S. Choi // J Korean Med Sci. – 2015. – Vol. 30, No 2. – P. 140-144.

Lewis GD, Bossone E, Naeije R, et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation 2013; 128: 1470–1479.

Overbeek S. A. [et al.] Cigarette Smoke-Induced Collagen Destruction; Key to Chronic Neutrophilic Airway Inflammation? [Text] // PLoS One. – 2013. – Vol. 8, No 1. – P. e55612.

Pedersen, A.E. CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells does not inhibit the action of IL-2 [Text] / A.E. Pedersen, J.P. Lauritsen // Scand J Immunol. – 2009. – Vol.70, No 1. – P. 40-43.

Riise G.C. et al. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis [Text] // Eur. Respir. J. – 1994. – Vol. 7, No 9. – P. 1673-1677.

Shirai T. et al. Correlation between peripheral blood T-cell profiles and clinical and inflammatory parameters in stable COPD [Text] // Allergol Int. – 2010. – Vol. 59. – P. 75–82.

Weitzenblum E., Chaouat A., Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease. - Pneumonol Alergol Pol. 2013;81(4):390-8.

Woodruff P.G. [et al.] Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management [Text] // Lancet. – 2015. – Vol. 385, No 9979. – P. 1789-1798.

Wright J. L., Levy R. D., Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605–609.